Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Perospirone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 6/20 | 0.96 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.96 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.96 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.96 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.96 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.96 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.96 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.96 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.96 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.96 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.96 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.96 |
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.71 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.71 |
| ▸ | HTR7 known ✓ | P34969 | 4/20 | 0.71 |
| ▸ | HTR6 known ✓ | P50406 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.96 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perospirone SCHEMBL5435087 | 1.00 | HTR1A (0.96) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL1155757 | 0.99 | HTR1A (0.98) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL28506465 | 0.99 | HTR1A (0.98) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL29846330 | 0.99 | HTR1A (0.98) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL30061058 | 0.98 | HTR1A (1.00) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL120579 | 0.98 | HTR1A (1.00) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL6691734 | 0.98 | HTR1A (1.00) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL1651000 | 0.96 | HTR1A (0.96) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL28054292 | 0.94 | HTR1A (0.89) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| SCHEMBL7283429 | 0.86 | HTR1A (0.79) | HTR1ALMNACHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765352-A4 | ANTAGONIZING AN ADENOSINE A2A RECEPTOR TO AMELIORIATE ONE OR MORE COMPONENTS OF ADDICTIVE BEHAVIOR | UNIV CALIFORNIA (US) | 2009-07-08 | — | — | EP | claimed |
| US-20090137662-A1 | SYNERGY OF DOPAMINE D2 AND ADENOSINE A2 RECEPTORS ACTIVATES PKA SIGNALING VIA BETA/GAMMA DIMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-05-28 | — | — | US | claimed |
| EP-1765352-A2 | ANTAGONIZING AN ADENOSINE A2A RECEPTOR TO AMELIORIATE ONE OR MORE COMPONENTS OF ADDICTIVE BEHAVIOR | The Regents of the University of California (US) | 2007-03-28 | — | — | EP | claimed |
| US-20060128708-A1 | Antagonizing an adenosine A2A receptor to ameliorate one or more components of addictive behavior | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-06-15 | — | — | US | claimed |
| WO-2006009698-A2 | ANTAGONIZING AN ADENOSINE A2A RECEPTOR TO AMELIORIATE ONE OR MORE COMPONENTS OF ADDICTIVE BEHAVIOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | WO | claimed |
| WO-2003082211-A2 | SYNERGY OF DOPAMINE D2 AND ADENOSINE A2 RECEPTORS ACTIVATES PKA SIGNALING VIA BETA/GAMMA DIMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-10-09 | — | — | WO | claimed |
| CN-117982442-A | Parpirone hydrochloride hydrophilic gel skeleton controlled release tablet and preparation method and application thereof | 西南医科大学 | 2024-05-07 | — | — | CN | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| CN-112225732-B | Crystal form of pirone hydrochloride hydrate and preparation method thereof | 四川科瑞德制药股份有限公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-4260847-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-18 | — | — | EP | disclosed |
| CN-115707701-A | High-purity perospirone and preparation method and application thereof | 四川科瑞德制药股份有限公司 | 2023-02-21 | — | — | CN | disclosed |
| US-11215607-B2 | Biomarker for diagnosis of irritable bowel syndrome | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-01-04 | — | — | US | disclosed |
| CN-112225732-A | Novel perospirone hydrochloride hydrate crystal form and preparation method thereof | 四川科瑞德制药股份有限公司 | 2021-01-15 | — | — | CN | disclosed |
| EP-1666468-A1 | CRF ANTAGONISTS AND HETEROBICYCLIC COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-1637531-A1 | METHANESULFONIC ACID SALT OF PYRAZOLOPYRIMIDINE COMPOUND, CRYSTAL THEREOF, AND PROCESS FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
| WO-2006009698-A2 | ANTAGONIZING AN ADENOSINE A2A RECEPTOR TO AMELIORIATE ONE OR MORE COMPONENTS OF ADDICTIVE BEHAVIOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | WO | disclosed |
| EP-1602373-A1 | OCULAR HYPOTENSIVE AGENT | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-20040082653-A1 | Remedies for depression containing ep1 antagonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1369129-A1 | REMEDIES FOR DEPRESSION CONTAINING EP1 ANTAGONIST AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003082211-A2 | SYNERGY OF DOPAMINE D2 AND ADENOSINE A2 RECEPTORS ACTIVATES PKA SIGNALING VIA BETA/GAMMA DIMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082653-A1 | Remedies for depression containing ep1 antagonist as the active ingredient | PTGER1, PTGER2, PTGS1 | HTR1A 13/4885CHRM2 199/4885ADRA2A 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.